AstraZeneca drops or divests a slate of drugs in latest quarterly update; Pierre Fabre extends a diagnostic collaboration with Roche
→ With profits in decline as generic Crestor competition bits into its cash flow, AstraZeneca noted the end of several in-house programs today as they cut some early-stage efforts and indicated the divestiture of others. Two mid-stage drugs are gone from the pipeline, with the rheumatoid arthritis drug mavrilimumab now at Kiniksa and inebelizumab handed off to their spinout Viela. MEDI-565, a BiTE partnered with Amgen, is out, along with the Sjögren’s syndrome drug MEDI4920 (divested) and MEDI7734 as well as the atopic dermatitis therapy MEDI9314.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.